Market closedNon-fractional
Shattuck Labs/STTK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Shattuck Labs
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Ticker
STTK
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Austin, United States
Employees
75
Website
www.shattucklabs.com
Shattuck Labs Metrics
BasicAdvanced
$211M
Market cap
-
P/E ratio
-$1.91
EPS
1.86
Beta
-
Dividend rate
Price and volume
Market cap
$211M
Beta
1.86
Financial strength
Current ratio
9.148
Quick ratio
8
Long term debt to equity
2.479
Total debt to equity
3.116
Management effectiveness
Return on assets (TTM)
-34.74%
Return on equity (TTM)
-59.40%
Valuation
Price to revenue (TTM)
72.826
Price to book
1.62
Price to tangible book (TTM)
1.62
Price to free cash flow (TTM)
-2.775
Growth
Revenue change (TTM)
282.93%
Earnings per share change (TTM)
-17.65%
3-year revenue growth (CAGR)
-33.49%
3-year earnings per share growth (CAGR)
3.07%
What the Analysts think about Shattuck Labs
Analyst Ratings
Majority rating from 6 analysts.
Shattuck Labs Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.1M
57.14%
Net income
-$19M
5.11%
Profit margin
-1,681.81%
-33.11%
Shattuck Labs Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.50
-$0.65
-$0.41
-$0.37
-
Expected
-$0.52
-$0.52
-$0.57
-$0.45
-$0.41
Surprise
-3.33%
25.20%
-27.84%
-17.26%
-
Shattuck Labs News
AllArticlesVideos
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
GlobeNewsWire·4 weeks ago
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
GlobeNewsWire·1 month ago
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Shattuck Labs stock?
Shattuck Labs (STTK) has a market cap of $211M as of July 27, 2024.
What is the P/E ratio for Shattuck Labs stock?
The price to earnings (P/E) ratio for Shattuck Labs (STTK) stock is 0 as of July 27, 2024.
Does Shattuck Labs stock pay dividends?
No, Shattuck Labs (STTK) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Shattuck Labs dividend payment date?
Shattuck Labs (STTK) stock does not pay dividends to its shareholders.
What is the beta indicator for Shattuck Labs?
Shattuck Labs (STTK) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Shattuck Labs stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.